Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3189 Real-world outcomes of patients with neuroendocrine liver metastases treated with trans-arterial radioembolization: Results from CIRT, a large European prospective multi-centre observational study

Introduction: Trans-arterial radioembolization (TARE) is a treatment option for patients with liver dominant metastases from neuroendocrine tumors (mNET). The CIRSE Registry for SIR-Spheres Therapy (CIRT) is a European prospective multi-centre observational study conducted by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Helmberger T

Authors: Helmberger T, Schaefer N, Pech M, Pfammatter T, Maleux G,

Keywords: liver metastases, observational study, yttrium-90, trans-arterial radioembolization, registry, therapeutic embolization, SIRT,

#3172 Peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE following liver directed therapy (LDT) in neuroendocrine tumors (NETs): Hepatotoxicity and impact on progression-free survival (PFS)

Introduction: PRRT (Lu-DOTATATE) and LDT (e.g. hepatic artery embolization) are commonly used in treating liver dominant NETs. Hepatotoxicity from PRRT in the setting of metastatic disease and prior liver-directed therapy is an important consideration. There is a concern for hepatotoxicity in patients receiving PRRT based on the literature, but there is limited data on patients who may have had a prior liver injury from LDT.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Badawy M

Authors: Badawy M, Halfdanarson T, Johnson G, Hobday T, Young J,

Keywords: hepatotoxicity, PRRT (LU-DOTATATE), liver targeted therapy, progression-free survival, NEN, NET,

#1894 Survival Analysis after i.a. 90Y-DOTATATE PRRT, in Patients with Non-Resectable, Advanced, Progressive, Liver-Dominant Neuroendocrine Neoplasms

Introduction: A

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Nowicki M, Kolasińska-Ćwikła A, Lewczuk A, Sankowski A, Bodei L,

Keywords: intra-arterial PRRT, progressive GEP-NENs, liver dominant,